Boston Scientific (NYSE:BSX) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Boston Scientific (NYSE:BSX) in a research report report published on Wednesday,Benzinga reports. Needham & Company LLC currently has a $121.00 target price on the medical equipment provider’s stock.

BSX has been the topic of several other research reports. Truist Financial raised their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, July 24th. Canaccord Genuity Group raised their price objective on shares of Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday. Raymond James Financial raised their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 price objective on shares of Boston Scientific in a report on Monday. Finally, Barclays raised their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Buy” and a consensus target price of $120.67.

Boston Scientific Stock Down 1.9%

Shares of NYSE:BSX opened at $95.78 on Wednesday. The firm’s 50 day moving average price is $103.30 and its 200 day moving average price is $102.08. The stock has a market cap of $141.91 billion, a price-to-earnings ratio of 57.01, a price-to-earnings-growth ratio of 2.35 and a beta of 0.61. Boston Scientific has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm’s revenue was up 22.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts predict that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Boston Scientific by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after buying an additional 2,545,381 shares during the last quarter. State Street Corp grew its position in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after buying an additional 713,379 shares during the last quarter. Geode Capital Management LLC grew its position in Boston Scientific by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after buying an additional 622,602 shares during the last quarter. Norges Bank purchased a new position in Boston Scientific in the 2nd quarter valued at $2,089,937,000. Finally, Invesco Ltd. boosted its position in shares of Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after purchasing an additional 226,578 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.